"Leukotriene Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
| Descriptor ID |
D020024
|
| MeSH Number(s) |
D06.347.565 D27.505.696.399.450.565
|
| Concept/Terms |
Leukotriene Antagonists- Leukotriene Antagonists
- Receptor Antagonists, Leukotriene
- Antagonists, Leukotriene Receptor
- Leukotriene Receptor Antagonists
- Antagonists, Leukotriene
|
Below are MeSH descriptors whose meaning is more general than "Leukotriene Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Leukotriene Antagonists".
This graph shows the total number of publications written about "Leukotriene Antagonists" by people in this website by year, and whether "Leukotriene Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 2 | 1 | 3 |
| 2009 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 5 | 1 | 6 |
| 2018 | 4 | 1 | 5 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukotriene Antagonists" by people in Profiles.
-
Montelukast and Coronavirus Disease 2019: A Scoping Review. Iran J Allergy Asthma Immunol. 2021 Aug 07; 20(4):384-393.
-
Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19. Pharmacology. 2021; 106(9-10):469-476.
-
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. Eur J Pharmacol. 2021 Aug 05; 904:174196.
-
Montelukast's ability to fight COVID-19 infection. J Asthma. 2021 10; 58(10):1348-1349.
-
Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug Discov Today. 2020 12; 25(12):2076-2079.
-
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Med Hypotheses. 2020 Oct; 143:109883.
-
Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope. 2019 03; 129(3):551-557.
-
Comparison of the efficacy and mechanisms of intranasal budesonide, montelukast, and their combination in treatment of patients with seasonal allergic rhinitis. Int Forum Allergy Rhinol. 2018 11; 8(11):1242-1252.
-
Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. Respir Med. 2018 09; 142:15-22.
-
Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial. PLoS One. 2018; 13(4):e0193564.